ISSN 1662-4009 (online)

ey0016.4-14 | Mechanism of the Year | ESPEYB16

4.14. IGF-2 preprograms maturing macrophages to acquire oxidative phosphorylation-dependent anti-inflammatory properties

L Du , L Lin , Q Li , K Liu , Y Huang , X Wang , K Cao , X Chen , W Cao , F Li , C Shao , Y Wang , Y Shi

To read the full abstract: Cell Metab. 2019 4;29:1363–1375.Mesenchymal stem and/or stromal cells (MSCs) regulate immune system and have been associated with inflammatory and autoimmune diseases. The IGF system is mainly known for its role in the regulation of growth, development and metabolism. A possible role of IGF-I in inflammation has recently been proposed [1, 2], whereas the e...

ey0020.9-14 | Obesity and Insulin/Glucose Metabolism | ESPEYB20

9.14. The bad rainbow of COVID-19 time: effects on glucose metabolism in children and adolescents with obesity and overweight

C Giannini , N Polidori , F Chiarelli , A Mohn

Brief summary: Giannini et al. report a timely study on the impact of COVID-19 restrictions on glucose metabolism in children and adolescents with obesity and overweight. They compared data from 741 children over a 13-year period, before and during the COVID-19 pandemic. They found that children in the COVID-19 restriction group did not have significantly increased values of Body Mass Index (BMI), but they did exhibit higher values of Waist Circumference (WC), Waist/H...

ey0018.8-11 | New Hope | ESPEYB18

8.11. New Horizons: Novel adrenal regenerative therapies

SR Bornstein , M Malyukov , C Heller , CG Ziegler , G Ruiz-Babot , A Schedl , B Ludwig , C Steenblock

J Clin Endocrinol Metab. 2020; 105(9): 3103–3107.https://pubmed.ncbi.nlm.nih.gov/32629476/In this narrative review, the authors discuss the potential role of novel regenerative therapies for the treatment of adrenal insufficiency, including gene therapy and cell replacement strategies. More specifically, the authors discuss the heterogeneity in adrenal function in patients with Addison...

ey0019.11-8 | New predictors of obesity development | ESPEYB19

11.8. Why do humans undergo an adiposity rebound? Exploring links with the energetic costs of brain development in childhood using MRI-based 4D measures of total cerebral blood flow

JE Aronoff , A Ragin , C Wu , M Markl , S Schnel , A Shaibani , C Blair , CW Kuzawa

kuzawa@northwestern.edu Int J Obes (Lond). 2022 May;46(5):1044–1050. doi: 10.1038/s41366-022-01065-8. Epub 2022 Feb 8. https://pubmed.ncbi.nlm.nih.gov/35136192/Brief Summary: This cross-sectional study measured total cerebral blood flow (TCBF) by MRI in 82 healthy individuals (ages 0&#...

ey0018.2-13 | Gestational Diabetes Mellitus: Neonatal and Long-term Consequences | ESPEYB18

2.13. Predictors of neonatal adiposity and associations by fetal sex in women with gestational diabetes mellitus and normal glucose-tolerant women

K Benhalima , A De Landtsheer , P Van Crombrugge , C Moyson , J Verhaeghe , H Verlaenen , C Vercammen , T Maes , E Dufraimont , C De Block , Y Jacquemyn , A Laenen , R Devlieger , C Minschart , C Mathieu

Acta Diabetol. 2021 Mar;58(3):341–354. doi: 10.1007/s00592-020-01619-0. PMID: 33216207.The key findings of this multi-centre prospective cohort study were that neonates born to mothers treated for Gestational diabetes mellitus (GDM) (by lifestyle or medication, e.g. insulin or metformin) had high rates of macrosomia but similar adiposity to those born of mothers with normal glucose...

ey0018.4-11 | New Perspectives | ESPEYB18

4.11. Genetic architecture associated with familial short stature

Lin Y , Cheng C , Wang C , Liang W , Tang C , Tsai L , Chen C , Wu J , Hsieh A , Lee M , Lin T , Liao C , Huang S , Zhang Y , Tsai C , Tsai F

J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgaa131. doi: 10.1210/clinem/dgaa131. PMID: 32170311Genetic control of height has been widely explored using genome-wide association studies (GWAS) in multi-ethnic populations (1-4). Although familial short stature (FSS) is the most common type of short stature, its genetic profile and impact on bone metabolism remains to be investigated. This GWAS...

ey0018.3-7 | Follow-up paper from the 2018 Yearbook | ESPEYB18

3.7. A Novel homozygous mutation in the solute carrier family 26 member 7 gene causes thyroid dyshormonogenesis in a girl with congenital hypothyroidism

P Hermanns , C Claszen , J Pohlenz

Thyroid. 2020;30:1831–1833. doi: 10.1089/thy.2020.0293.Every year, we report on new genes that have been associated with congenital hypothyroidism. But it is the first time in all these years that, following the first description, other groups from different continents confirm the first reports in independent cohorts in such a short time after publication.This is ...

ey0021.8-8 | Important for Clinical Practice | ESPEYB21

8.8. Paediatric Cushing syndrome: a prospective, multisite, observational cohort study

C Tatsi , C Kamilaris , M Keil , L Saidkhodjaeva , FR Faucz , P Chittiboina , CA Stratakis

Brief Summary: This large patient cohort of children with endogenous Cushing syndrome describes their anthropometric, clinical, and biochemical characteristics, as well as their associated complications and outcomes. The findings inform diagnosis, treatment, and management.Comment: Endogenous Cushing syndrome is rare in children and adolescents, and has variable manifestations (1-6). This prospective, multicenter cohort of 342 children and adolescents ag...

ey0019.12-11 | Hyperlipidemia | ESPEYB19

12.11. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

H. Wang J, Zhao J, Yan C, Xi C, Wu C, Zhao J, Li F, Ding Y, Zhang R, Qi S, Li X, Liu C, Hou W, Chen H, Wang Y, Wu D, Chen K, Jiang H, Huang H, Liu

Cell Metabolism 2022;34(5):667-80.e6. doi: 10.1016/j.cmet.2022.03.006Brief Summary: In preclinical models and a phase 1 trial, a powerful new lipid small molecule was shown to act through a mechanism distinct from those of known hypolipidemic agents. Targeting HNF-1α may be a new therapeutic strategy.Comment: Familial hypercholesterolemia (FH) is the most common...

ey0018.8-4 | Important for Clinical Practice | ESPEYB18

8.4. Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia

C Kamrath , MF Hartmann , J Pons-Kuhnemann , SA Wudy

Metabolism. 2020; 112: 154354.https://pubmed.ncbi.nlm.nih.gov/32916150/In order to better define treatment groups and improve treatment monitoring, the authors performed a retrospective metabotyping analysis using 24-h GC–MS urinary steroid metabolome measurements in young prepubertal children (n=109; age 7.0–1.6 years) with classical congenital adrenal hyperplasia (CAH) ...